| Ms Ellen Lucille Wicklund, DC | |
|
206 Main St Sw, Ronan, MT 59864 | |
| (406) 676-0170 | |
| (406) 676-0160 |
| Full Name | Ms Ellen Lucille Wicklund |
|---|---|
| Gender | Female |
| Speciality | Chiropractic |
| Experience | 22 Years |
| Location | 206 Main St Sw, Ronan, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902970312 | NPI | - | NPPES |
| P00067474 | Other | RR MEDICARE | |
| 40743 | Other | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 1050 (Montana) | Primary |
| Provider Name | Ronan Chiropractic Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1649374794 PECOS PAC ID: 1254222052 Enrollment ID: O20040322001482 |
News Archive
The Jackson Clarion-Ledger on Wednesday examined how some U.S. residents who cannot afford health insurance are reducing the amount of medications they take or cutting doses, as well as seeing the doctor less frequently, to save money.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
Global engineering and healthcare technologies company, Renishaw, is attending the second annual International 3D Printing in Medicine Conference in Mainz, Germany on May 19th-20th. Renishaw will demonstrate the opportunities that additive manufacturing (AM) creates in craniomaxillofacial surgery, by exhibiting its bespoke implants and providing demonstrations of its new implant design software, Additive-manufacture for Design-led Efficient Patient Treatment (ADEPT).
Fifteen projects announced today, 31 January 2018, will develop new healthcare technologies to tackle international health challenges, ranging from the prevention of limb loss by Syrian refugees to faster diagnosis and treatment for parasitic diseases such as malaria.
Researchers at Lund University in Sweden are testing a treatment for type 2 diabetes which targets the disease mechanism itself - and not just the symptoms. For the first time, knowledge about the individual patient's genetic risk profile is being used. The treatment completely restores the capacity to secrete insulin, which is impaired by the risk gene.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Ellen Lucille Wicklund, DC 206 Main St Sw, Ronan, MT 59864 Ph: (406) 676-0170 | Ms Ellen Lucille Wicklund, DC 206 Main St Sw, Ronan, MT 59864 Ph: (406) 676-0170 |
News Archive
The Jackson Clarion-Ledger on Wednesday examined how some U.S. residents who cannot afford health insurance are reducing the amount of medications they take or cutting doses, as well as seeing the doctor less frequently, to save money.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
Global engineering and healthcare technologies company, Renishaw, is attending the second annual International 3D Printing in Medicine Conference in Mainz, Germany on May 19th-20th. Renishaw will demonstrate the opportunities that additive manufacturing (AM) creates in craniomaxillofacial surgery, by exhibiting its bespoke implants and providing demonstrations of its new implant design software, Additive-manufacture for Design-led Efficient Patient Treatment (ADEPT).
Fifteen projects announced today, 31 January 2018, will develop new healthcare technologies to tackle international health challenges, ranging from the prevention of limb loss by Syrian refugees to faster diagnosis and treatment for parasitic diseases such as malaria.
Researchers at Lund University in Sweden are testing a treatment for type 2 diabetes which targets the disease mechanism itself - and not just the symptoms. For the first time, knowledge about the individual patient's genetic risk profile is being used. The treatment completely restores the capacity to secrete insulin, which is impaired by the risk gene.
› Verified 4 days ago
Dr. Eric V Boughton, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 63228 Us Highway 93, Ronan, MT 59864 Phone: 406-871-8347 | |
Ronan Chiropractic Inc Chiropractor Medicare: Medicare Enrolled Practice Location: 206 Main St Sw, Ronan, MT 59864 Phone: 406-676-0170 Fax: 406-676-0160 |